Carisma Therapeutics is a biotech company that develops novel chimeric antigen receptor macrophage technology to treat solid tumors.
Carisma Therapeutics is a biotech company that develops novel chimeric antigen receptor macrophage technology to treat solid tumors. Its cell therapies apply powerful chimeric antigen receptor technology and adoptive cell transfer in cancer therapy and to macrophages that infiltrate the solid tumor micro-environment that enables solid tumor patients to receive strong cellular immunotherapy and cancer treatments. The company's technology leverages advances in macrophage biology, chimeric antigen receptor engineering, and adoptive cellular therapy for the treatment of human disease.Founded in 2016 by Michael Klichinsky and Saar Gill, Carisma Therapeutics is headquartered in Philadelphia, Pennsylvania.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Sep 21, 2022 | Series C | $30M | 12 | — | — | Detail |
Mar 1, 2021 | Series B | $12M | 12 | — | — | Detail |
Jan 7, 2021 | Series B | $47M | 10 | SymBiosis LLC | — | Detail |
Aug 8, 2019 | Series A | $6M | 2 | AbbVie Biotech Ventures HealthCap | — | Detail |
Jun 27, 2018 | Series A | $53M | 9 | AbbVie Biotech Ventures HealthCap | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
4BIO Capital | — | Series C |
AbbVie | — | Series C |
Agent Capital | — | Series C |
HealthCap | — | Series C |
Livzon Pharmaceutical Group | — | Series C |
MRL Ventures Fund | — | Series C |
Penn Medicine Co-Investment Program | — | Series C |
Pictet Alternative Advisors | — | Series C |
Solasta Ventures | — | Series C |
SymBiosis LLC | — | Series C |